Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This open-label study aims to evaluate the impact of BI 10773 treatment on glomerular
filtration rate under controlled conditions of euglycaemia and hyperglycaemia in subjects
with type 1 diabetes mellitus with or without renal hyperfiltration and to characterize the
safety and efficacy of BI 10773 25 mg QD as add-on therapy to insulin in these subjects.